Therapeutic strategies targeting uPAR potentiate anti–PD-1 efficacy in diffuse-type gastric cancer

The diffuse-type gastric cancer (DGC) is a subtype of gastric cancer (GC) associated with low HER2 positivity rate and insensitivity to chemotherapy and immune checkpoint inhibitors. Here, we identify urokinase-type plasminogen activator receptor (uPAR) as a potential therapeutic target for DGC. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Long, Wang, Long, Zhang, Junchang, Zhou, Huinian, Yang, Zhiliang, Wang, Yan, Cai, Weiwen, Wen, Fei, Jiang, Xiangyan, Zhang, Tiansheng, Ye, Huili, Long, Bo, Qin, Junjie, Shi, Wengui, Guan, Xiaoying, Yu, Zeyuan, Yang, Jing, Wang, Qi, Jiao, Zuoyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132454/
https://www.ncbi.nlm.nih.gov/pubmed/35613265
http://dx.doi.org/10.1126/sciadv.abn3774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132454/
https://www.ncbi.nlm.nih.gov/pubmed/35613265
http://dx.doi.org/10.1126/sciadv.abn3774

Ejemplares similares